Venus Remedies Limited has issued a formal communication to shareholders, announcing the opening of a special window for the re-lodgement of transfer requests for physical shares. The company subsequently filed a newspaper publication notice dated May 5, 2026, with both the National Stock Exchange of India Ltd. and BSE Limited, in compliance with applicable regulatory requirements under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Regulatory Basis for the Announcement

The special window has been opened in accordance with SEBI Circular No. HO/38/13/11/2026-MIRSD-POD/13750/2026, issued on January 30, 2026. As per the circular, the special window is open from February 05, 2026 to February 04, 2027, for re-lodgement of transfer deeds that were lodged before April 1, 2019 but were rejected, returned, or left unattended due to deficiency in documents, process, or otherwise. All such securities will be transferred only in demat form after due process as outlined in the SEBI circular.

Notice to Shareholders

Venus Remedies has advised shareholders who have not yet converted their eligible physical shares to utilise this final opportunity. Shareholders are required to submit requests along with requisite documents and original share certificates to the Company's Registrar and Transfer Agent (RTA). The RTA contact details are as follows:

Social Media Dissemination

Venus Remedies also disseminated the shareholder notice through its official social media platforms to ensure broad shareholder reach and transparency. The following table summarises the platforms used for this communication:

Company Details

The newspaper publication notice was signed by the Company Secretary and digitally authenticated on May 5, 2026. The initial shareholder communication was signed and authenticated on May 4, 2026. Key corporate details of Venus Remedies Limited are as follows:

Venus Remedies has requested both exchanges to take the above communication on record.

Source: None/Company/INE411B01019/01d58e000e684a1d.pdf

Venus Remedies Limited has announced the opening of a special window for re-lodgement of transfer requests of physical shares through its official social media channels. The pharmaceutical company informed both the National Stock Exchange of India and BSE Limited about this development on 08.04.2026.

Regulatory Compliance and Communication

The announcement was made pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has shared links to posts made on its official social media handles to ensure widespread dissemination of this important information to shareholders.

SEBI Circular Implementation

This special window initiative is in accordance with SEBI Circular No. HO/38/13/11(2)2026-MIRSD-POD/I/3750/2026 dated 30.01.2026. The circular appears to provide guidelines for companies to offer shareholders an opportunity to re-lodge their physical share transfer requests that may have been previously rejected or require reprocessing.

Social Media Outreach Strategy

Venus Remedies has adopted a comprehensive digital communication approach by posting the notice across multiple social media platforms:

• Facebook: Shared on the company's official Facebook page
• LinkedIn: Posted as a professional update for stakeholders
• Instagram: Visual communication through the company's Instagram account
• X Platform: Announced via the official Twitter handle

This multi-platform approach ensures maximum reach to shareholders who may hold physical shares and need to complete transfer procedures.

Company Information

Venus Remedies Limited operates from multiple locations with its registered office in Chandigarh and corporate office in Panchkula, Haryana. The company maintains manufacturing units in Panchkula and Baddi, along with an international presence through Venus Pharma GmbH in Germany. The communication was signed by Company Secretary Neha, emphasizing the formal nature of this regulatory disclosure.